RNLS labeling in IPMN and PDAC lesions. by Yasheen Gao (6090842)

Subjects:

Association between high and low RNLS levels with survival in locally advanced/borderline resectable PDAC. by Yasheen Gao (6090842)

Subjects:

RNLS labeling in PanIN and MCN lesions. by Yasheen Gao (6090842)

Subjects:

Patient characteristics for low vs. high plasma RNLS levels in patients with locally advanced/borderline resectable (LA/BR) pancreatic adenocarcinoma (PDAC). by Yasheen Gao (6090842)

Subjects:

Table_1_Non-invasive Biomarkers of Liver Inflammation and Cell Death in Response to Alcohol Detoxification.DOCX by Manuela G. Neuman (11086812)

“…</p>Results<p>Patients consumed a mean of 204 ± 148 g/day alcohol with a heavy drinking duration of 15.3 ± 11.0 years. …”

Immunofluorescence microscopy of Vpu-FLAG and candidate cofactor SNX3. by Charlotte A. Stoneham (10819125)

Image_5_Changes in BMI and physical activity from youth to adulthood distinguish normal-weight, metabolically obese adults from those who remain healthy.tif by A. Viitasalo (13224681)

The combination of miR-425 and miR-155 resulted in greater repression of <i>NPPA</i> expression than a higher concentration of either miRNA alone. by Sara Vandenwijngaert (390970)

(a) Convex, triangular, and concave geometry at a constant vertex angle. by Amirhossein Favakeh (21417884)

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

“…Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparation (IVIG) octagam®.…”

(A) Cost-effectiveness plane in healthcare system perspectives; (B) Cost-effectiveness acceptability curve in healthcare system perspectives; (C) Cost-effectiveness plane in societ... by Jae-Heung Cho (798319)

Data_Sheet_1_Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.... by Zhibo Zhang (8956400)

“…At least 20% decreases of the biomarkers from baseline were considered as meaningful improvements after 6 weeks of treatment with immune checkpoint inhibitors (ICIs). …”

MAb binding to JR-FL gp160ΔCT E168K+N189A in BN-PAGE “shifts”. by Tommy Tong (426980)

Ras Effector Mutant Expression Suggest a Negative Regulator Inhibits Lung Tumor Formation by Guillaume Vandal (469742)

“…Over 70% of patients with non-small cell lung cancer (NSCLC) are diagnosed at a late stage, with a 5-year survival below 10%. …”

Presentation_1_Risk of severe COVID-19 infection in persons with diabetes during the first and second waves in Denmark: A nationwide cohort study.pdf by Jacob V. Stidsen (8560017)

“…However, when mortality was restricted to the hospitalized population, the crude mortality fell from 26.8% to 19.6% in persons with diabetes, while only a minor decrease was seen in persons without diabetes (from 16.7% to 15.5%).…”

Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial by Christa Kasang (345821)

“…Secondary endpoints: Prednisolone-treatment decreased immune activation (sCD14, suPAR, CD38/HLA-DR/CD8+) and increased CD4-counts (+77.42 ± 5.70 cells/μl compared to -37.42 ± 10.77 cells/μl under placebo, p < 0.0001). …”

Data_Sheet_1_Short-term effects of air pollutants on outpatients with psoriasis in a Chinese city with a subtropical monsoon climate.docx by Ting Wang (16292)

“…An increase of 10 μg/m³ of NO₂ was associated with a 2.1% (95% CI: 0.7–3.5%) increase in outpatients with psoriasis, and a decrease of 10 μg/m³ of O₃ was associated with an 0.8% (95% CI: 0.4–1.2%) increase in outpatients with psoriasis. …”